December 27th 2023
Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.
December 20th 2023
Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.
A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.
December 13th 2023
Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.
Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
October 21st 2023
Hans Hammers, MD, PhD, discusses a case presentation of a patient with advanced renal cell carcinoma.
September 18th 2023
Hans Hammers, MD, PhD, discusses areas of controversy and remaining unmet needs in the treatment of patients with renal cell carcinoma.
August 23rd 2023
Hans Hammers, MD, PhD, discusses ongoing and planned investigations with the use of HIF2α inhibitors and triplet therapies in patients with advanced renal cell carcinoma.
April 26th 2023
The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
The panel discusses the best approaches to treating patients with non-clear cell RCC.
April 19th 2023
The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.
Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.
April 12th 2023
The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.
April 5th 2023
Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.
The panel provides an overview of novel double combination therapies currently under investigation.
March 31st 2023
Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.
The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.
March 23rd 2023
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.